RecruitingPhase 2NCT06369155

Azenosertib in Uterine Serous Carcinoma: Biomarker Study

A Biomarker Study of the Wee1 Inhibitor Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma

Sponsor

Joyce Liu, MD

Enrollment

25 participants

Start Date

Mar 5, 2025

Study Type

INTERVENTIONAL

Conditions

Uterine Cancer Uterine Serous Carcinoma Uterine Carcinoma

Summary

This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma. The name of the study drug involved in this study is: -Azenosertib (a type of Wee1 inhibitor)

Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a drug called azenosertib (a WEE1 inhibitor) in women with recurrent or persistent uterine serous carcinoma (an aggressive type of uterine cancer), and collecting tissue samples to understand which biological markers predict response to treatment. **You may be eligible if...** - You have a confirmed diagnosis of recurrent or persistent uterine serous carcinoma - You have at least one measurable tumor on imaging - You have received prior platinum-based chemotherapy - You are able to undergo a fresh tumor biopsy at the start of treatment **You may NOT be eligible if...** - You have already received a WEE1 inhibitor - You have significant heart problems or blood abnormalities - You are pregnant or breastfeeding - You have uncontrolled brain metastases Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.